On the stock market since 2024, it operates in the world of health and science. It has 238 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 32% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $9.8M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 8 buys and 3 sells. Management buying with its own money is usually read as a good sign.
A loss of $1.1M against $9.8M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, WOK sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: WOK is a high-risk stock — not yet profitable, and its future rides on its product catching on.